The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Contributions of Interleukin-1 Receptor Signaling in Traumatic Brain Injury
|
|---|---|
| Published in |
Frontiers in Behavioral Neuroscience, January 2020
|
| DOI | 10.3389/fnbeh.2019.00287 |
| Pubmed ID | |
| Authors |
Jason G. Thome, Evan L. Reeder, Sean M. Collins, Poornima Gopalan, Matthew J. Robson |
| Abstract |
Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI. Acute phases of TBI are characterized by profound neuroinflammation, a process that stimulates the generation and release of proinflammatory cytokines including interleukin-1α (IL-1α) and IL-1β. Both forms of IL-1 initiate signaling by binding with IL-1 receptor type 1 (IL-1R1), a receptor with a natural, endogenous antagonist dubbed IL-1 receptor antagonist (IL-1Ra). The recombinant form of IL-1Ra has gained FDA approval for inflammatory conditions such as rheumatoid arthritis, prompting interest in repurposing these pharmacotherapies for other inflammatory diseases/injury states including TBI. This review summarizes the currently available preclinical and clinical literature regarding the therapeutic potential of inhibiting IL-1-mediated signaling in the context of TBI. Additionally, we propose specific research areas that would provide a greater understanding of the role of IL-1 signaling in TBI and how these data may be beneficial for the development of IL-1-targeted therapies, ushering in the first FDA-approved pharmacotherapy for acute TBI. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 19% |
| Student > Ph. D. Student | 8 | 17% |
| Student > Master | 5 | 10% |
| Student > Doctoral Student | 3 | 6% |
| Professor | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 15 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 14 | 29% |
| Medicine and Dentistry | 5 | 10% |
| Agricultural and Biological Sciences | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Mathematics | 1 | 2% |
| Other | 5 | 10% |
| Unknown | 17 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2020.
All research outputs
#20,601,627
of 23,189,371 outputs
Outputs from Frontiers in Behavioral Neuroscience
#2,885
of 3,233 outputs
Outputs of similar age
#381,191
of 455,699 outputs
Outputs of similar age from Frontiers in Behavioral Neuroscience
#53
of 59 outputs
Altmetric has tracked 23,189,371 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,233 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 455,699 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.